Definition of erythroid cell-positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection.


Journal

Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 24 08 2020
revised: 23 11 2020
accepted: 26 11 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 31 12 2020
Statut: ppublish

Résumé

Biomarkers to assess the risk of developing severe respiratory syncytial virus (RSV) infection are needed. We conducted a meta-analysis of 490 unique profiles from six public RSV blood transcriptome datasets. A repertoire of 382 well-characterized transcriptional modules was used to define dominant host responses to RSV infection. The consolidated RSV cohort was stratified according to four traits: "interferon response" (IFN), "neutrophil-driven inflammation" (Infl), "cell cycle" (CC), and "erythrocytes" (Ery). We identified eight prevalent blood transcriptome phenotypes, of which three Ery+ phenotypes comprised higher proportions of patients requiring intensive care. This finding confirms on a larger scale data from one of our earlier reports describing an association between an erythrocyte signature and RSV disease severity. Further contextual interpretation made it possible to associate this signature with immunosuppressive states (late stage cancer, pharmacological immunosuppression), and with a population of fetal glycophorin A+ erythroid precursors. Furthermore, we posit that this erythrocyte cell signature may be linked to a population of immunosuppressive erythroid cells previously described in the literature, and that overabundance of this cell population in RSV patients may underlie progression to severe disease. These findings outline potential priority areas for biomarker development and investigations into the immune biology of RSV infection. The approach that we developed and employed here should also permit to delineate prevalent blood transcriptome phenotypes in other settings.

Identifiants

pubmed: 33377660
doi: 10.1002/ctm2.244
pmc: PMC7733317
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e244

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI112524
Pays : United States

Informations de copyright

© 2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Références

J Immunol. 2011 Oct 15;187(8):4245-55
pubmed: 21918196
Microb Pathog. 1992 Jun;12(6):409-14
pubmed: 1522795
J Infect Dis. 2013 Nov 15;208(10):1664-8
pubmed: 23901082
Genet Mol Res. 2016 Mar 24;15(1):
pubmed: 27050987
Nat Rev Immunol. 2014 Apr;14(4):271-80
pubmed: 24662387
BMC Bioinformatics. 2016 Jan 22;17:47
pubmed: 26801061
J Clin Virol. 2013 Dec;58(4):689-95
pubmed: 24140015
Am J Respir Crit Care Med. 1999 Oct;160(4):1263-8
pubmed: 10508817
Front Immunol. 2018 Mar 02;9:323
pubmed: 29552008
Am J Clin Pathol. 2004 Apr;121(4):482-8
pubmed: 15080299
PLoS Med. 2013 Nov;10(11):e1001549
pubmed: 24265599
PLoS One. 2015 Jul 10;10(7):e0131927
pubmed: 26162090
Viral Immunol. 2019 Mar;32(2):76-83
pubmed: 30499759
Nature. 2013 Dec 5;504(7478):158-62
pubmed: 24196717
Clin Exp Immunol. 2004 Oct;138(1):102-9
pubmed: 15373911
Annu Rev Immunol. 2017 Apr 26;35:337-370
pubmed: 28142321
Am J Respir Cell Mol Biol. 2018 Jun;58(6):717-726
pubmed: 29314865
mSystems. 2016 Jun 28;1(3):
pubmed: 27822537
Nucleic Acids Res. 2017 Jan 9;45(1):e1
pubmed: 27634930
Pediatrics. 2010 Dec;126(6):e1453-60
pubmed: 21098154
Nat Commun. 2018 Feb 15;9(1):694
pubmed: 29449546
Nat Med. 2018 Oct;24(10):1536-1544
pubmed: 30297899
Pediatrics. 2014 Aug;134(2):e620-38
pubmed: 25070304
Semin Immunol. 2015 Feb;27(1):58-66
pubmed: 25823891
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1104-1115
pubmed: 27135599
PLoS One. 2018 Jun 19;13(6):e0198555
pubmed: 29920518
Sci Transl Med. 2011 Sep 21;3(101):101ra92
pubmed: 21937757
Pediatr Infect Dis J. 2013 Feb;32(2):e68-76
pubmed: 23190772
J Immunol. 2018 Jun 15;200(12):4044-4058
pubmed: 29735482
Cell. 2011 Jan 21;144(2):296-309
pubmed: 21241896
Isr Med Assoc J. 2019 Feb;21(2):110-115
pubmed: 30772962
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Immunol. 2010 Nov 15;185(10):6198-204
pubmed: 20952675
J Infect Dis. 2017 Dec 27;217(1):24-34
pubmed: 29045741
Immunity. 2013 Apr 18;38(4):831-44
pubmed: 23601689
BMC Infect Dis. 2006 Dec 13;6:175
pubmed: 17166282
Immunity. 2008 Jul 18;29(1):150-64
pubmed: 18631455
J Trauma Acute Care Surg. 2017 Jul;83(1):144-150
pubmed: 28452894
J Allergy Clin Immunol. 2017 Jun;139(6):1997-2000.e4
pubmed: 27931976
J Infect Dis. 2017 Dec 27;217(1):134-146
pubmed: 29029245
Clin Exp Immunol. 2004 Jul;137(1):146-50
pubmed: 15196255
Arthritis Res Ther. 2018 May 2;20(1):85
pubmed: 29720240
Trends Immunol. 2019 Mar;40(3):181-185
pubmed: 30718046
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
PLoS One. 2014 Oct 14;9(10):e109760
pubmed: 25314013
Sci Transl Med. 2016 Jan 20;8(322):322ra11
pubmed: 26791949

Auteurs

Matthew C Altman (MC)

Benaroya Research Institute, Seattle, Washington.
University of Washington, Seattle, Washington.

Oceane Konza (O)

Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

Signe Hässler (S)

Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Immunology-Immunopathology-Immunotherapy (i3), Sorbonne Université, INSERM, Paris, France.

Federica Martina (F)

Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

Mohammed Toufiq (M)

Sidra Medicine, Doha, Qatar.

Mathieu Garand (M)

Sidra Medicine, Doha, Qatar.

Basirudeen Syed Ahamed Kabeer (BSA)

Sidra Medicine, Doha, Qatar.

Karolina Palucka (K)

Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.

Asuncion Mejias (A)

Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.

Octavio Ramilo (O)

Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.

Davide Bedognetti (D)

Sidra Medicine, Doha, Qatar.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Encarnita Mariotti-Ferrandiz (E)

Immunology-Immunopathology-Immunotherapy (i3), Sorbonne Université, INSERM, Paris, France.

David Klatzmann (D)

Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Immunology-Immunopathology-Immunotherapy (i3), Sorbonne Université, INSERM, Paris, France.

Damien Chaussabel (D)

Sidra Medicine, Doha, Qatar.

Classifications MeSH